Teva

Teva signs new $3B syndicated revolving credit facility

Tuesday, December 18, 2012 02:23 PM

Teva Pharmaceutical Industries, a global pharmaceutical company, has entered into a new five-year, $3 billion unsecured revolving credit facility, which replaces its existing $2.5 billion credit facility.

More... »

Teva, Handok to establish business venture in Korean pharma market

Monday, December 17, 2012 01:41 PM

Teva Pharmaceutical Industries, an Israel-based pharmaceutical company, and Handok Pharmaceuticals, a pharmaceutical/healthcare company in Korea, have agreed to establish a business venture in South Korea, allowing Teva to gain entrance into the Korean pharmaceutical market, currently valued at approximately $14 billion.

More... »

Prize4Life launches PRO-ACT, largest ALS trials database ever created

Friday, December 7, 2012 10:42 AM

Prize4Life, a nonprofit organization dedicated to accelerating discovery of treatments and a cure for ALS (amyotrophic lateral sclerosis, also known as Lou Gehrig's disease), launched the PRO-ACT (Pooled Resource Open-Access ALS Clinical Trials) database, the largest ALS clinical trial database ever created.

More... »

Teva names Oberman as CEO of Teva Americas Generics

Wednesday, November 7, 2012 12:14 PM

Teva Pharmaceutical, a global pharmaceutical company based in Israel, has made changes to its executive leadership team.

More... »

Teva Canada completes sale of Mirabel facility to Halo Pharmaceutical

Monday, August 6, 2012 11:38 AM

Teva Canada, a healthcare solutions provider, has completed the sale of its Mirabel manufacturing facility in Montreal to Halo Pharmaceutical, a contract development and manufacturing organization (CDMO) based in Parsippany, N.J.

More... »

Teva appoints two to executive team

Friday, August 3, 2012 11:07 AM

Teva Pharmaceutical, a global pharmaceutical company based in Israel, has appointed Dr. Carlo De Notaristefani as president and CEO of global operations and Aharon (Arik) Yaari as executive vice president of newly created community and institutional affairs.

More... »

Teva reports top-line results from phase III MS trial

Monday, June 18, 2012 03:30 PM

Teva Pharmaceutical, an Israel-based global pharmaceutical company, released positive top-line results from the GALA (Glatiramer Acetate Low-Frequency Administration) phase III trial showing that 40mg/1ml glatiramer acetate injection (GA) significantly reduced multiple sclerosis (MS) disease activity, while maintaining a favorable safety and tolerability profile.

More... »

Teva Canada sells Quebec facility to Halo Pharmaceutical

Monday, April 2, 2012 11:01 AM

Teva Canada has finalized an agreement under which Halo Pharmaceutical, a contract manufacturing organization based in Whippany, N.J., will acquire Teva's manufacturing facility in Mirabel, Quebec.

More... »

FDA approves BioSante’s Bio-T-Gel

Wednesday, February 15, 2012 03:59 PM

The FDA has approved Bio-T-Gel for the treatment of male hypogonadism (low testosterone levels), according to BioSante Pharmaceuticals.

More... »

Results of OncoGenex phase I/II Custirsen trial published

Friday, January 6, 2012 09:32 AM

OncoGenex Pharmaceuticals has reported results of a phase I/II study to determine the effectiveness of its investigational compound custirsen in conjunction with a gemcitabine/platinum-based regimen in patients with advanced non-small cell lung cancer (NSCLC).

More... »